Form 4: Journey Medical CFO Joseph Benesch Granted Significant Equity Awards

Journey Medical Corp's Chief Financial Officer, Joseph Benesch, was granted 28,907 restricted stock units and 41,860 stock options under the company's 2015 Stock Plan.

Summary

• Joseph Benesch, CFO of Journey Medical Corp (DERM), was granted 28,907 restricted stock units (RSUs) on June 17, 2025.
• These RSUs will vest in three annual installments: 9,636 shares on January 1, 2026, 9,636 shares on January 1, 2027, and 9,635 shares on January 1, 2028.
• Mr. Benesch was also granted 41,860 stock options with an exercise price of $6.31 per share on June 17, 2025.
• The stock options will vest in three annual installments: 13,953 shares on January 1, 2026, 13,953 shares on January 1, 2027, and 13,954 shares on January 1, 2028.
• The stock options have an expiration date of June 17, 2035.
• The transactions were made pursuant to the Issuer's 2015 Stock Plan, as amended, and are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The document reports a routine executive compensation grant, which is generally positive as it aligns management incentives with shareholder interests. There are no negative surprises or significant risks disclosed beyond the inherent market risk of equity ownership.

Positives

• The equity grants align the CFO's interests with those of shareholders, incentivizing long-term performance and value creation.
• The grants are part of a pre-arranged plan (Rule 10b5-1(c)), indicating a structured approach to executive compensation.

Risks

• The value of the granted restricted stock units and stock options is subject to the future performance of Journey Medical Corp's stock price, which could decline.

Future Outlook

The grants of restricted stock units and stock options are structured with future vesting schedules extending to January 1, 2028, indicating a long-term incentive for the CFO tied to the company's future performance.

Industry Context

Executive equity grants are a standard practice across industries, including the pharmaceutical and healthcare sectors, to attract, retain, and motivate key management personnel. These grants typically align management's financial interests with the long-term success and shareholder value of the company.

Comparison to Industry Standards

• The use of restricted stock units and stock options as part of executive compensation is a common practice in publicly traded companies, aligning with typical industry standards for incentivizing leadership.
• The vesting schedule over multiple years is standard for long-term incentive plans, similar to those observed in comparable companies within the specialty pharmaceutical or dermatology sectors.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to the Chief Financial Officer is a related party transaction, as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: The grants aim to align the CFO's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: May signal stability in executive leadership and a commitment to performance-based compensation, potentially influencing broader employee incentive structures.
• Management: Provides significant long-term incentives and compensation to the CFO, aiding in retention and motivation.

Next Steps

• The granted restricted stock units will vest in three tranches on January 1, 2026, January 1, 2027, and January 1, 2028.
• The granted stock options will vest in three tranches on January 1, 2026, January 1, 2027, and January 1, 2028, and can be exercised until June 17, 2035.

Key Dates

Keywords

Journey Medical Corp, DERM, SEC Form 4, Joseph Benesch, CFO, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, 10b5-1 Plan